Shots:
- Evotec to receive research funding and will be eligible for $160M/program as discovery, pre/ clinical, a commercial milestone along with royalties on sales of product emerges from the collaboration
- The collaboration will utilize Evotec’s RNA targeting platform to identify RNA sequences to target with small-molecule ligands aligned that can be developed into the first-in-class therapeutics
- The companies will jointly identify & develop small molecules targeting a range of RNA targets aligned with Takeda’s research and development areas
Click here to read full press release/ article | Ref: Evotec | Image: Wikipedia
The post Takeda Collaborates with Evotec on RNA Targeting Drug Development first appeared on PharmaShots.
